日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Safety and immunogenicity of an intranasal sendai virus-based vaccine for human parainfluenza virus type I and respiratory syncytial virus (SeVRSV) in adults

针对成人副流感病毒 I 型和呼吸道合胞病毒 (SeVRSV) 的鼻内仙台病毒疫苗的安全性和免疫原性

Felicia Scaggs Huang, David I Bernstein, Karen S Slobod, Allen Portner, Toru Takimoto, Charles J Russell, Michael Meagher, Bart G Jones, Robert E Sealy, Christopher Coleclough, Kristen Branum, Michelle Dickey, Kristen Buschle, Monica McNeal, Mat Makowski, Aya Nakamura, Julia L Hurwitz

Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infections

表达 hPIV-3 HN 或 F 的仙台病毒重组疫苗可引发保护性免疫,并与第二种重组体结合,以预防 hPIV-1、hPIV-3 和 RSV 感染

Xiaoyan Zhan, Karen S Slobod, Sateesh Krishnamurthy, Laura E Luque, Toru Takimoto, Bart Jones, Sherri Surman, Charles J Russell, Allen Portner, Julia L Hurwitz

A recombinant Sendai virus is controlled by CD4+ effector T cells responding to a secreted human immunodeficiency virus type 1 envelope glycoprotein

重组仙台病毒由对分泌型人类免疫缺陷病毒 1 型包膜糖蛋白作出反应的 CD4+ 效应 T 细胞控制

Scott A Brown, Julia L Hurwitz, Amy Zirkel, Sherri Surman, Toru Takimoto, Irina Alymova, Chris Coleclough, Allen Portner, Peter C Doherty, Karen S Slobod

The long noncoding region of the human parainfluenza virus type 1 f gene contributes to the read-through transcription at the m-f gene junction

人类副流感病毒 1 型 f 基因的长非编码区有助于 mf 基因连接处的通读转录

Tatiana Bousse, Tatyana Matrosovich, Allen Portner, Atsushi Kato, Yoshiyuki Nagai, Toru Takimoto